RA Capital Management's Schedule 13D Filing for SAB Biotherapeutics, Inc.

RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., filed a Schedule 13D with the SEC regarding their holdings in SAB Biotherapeutics, Inc. The filing discloses that the Fund holds 4,401,500 shares of common stock, Series B preferred stock convertible into up to 12,738,500 shares of common stock, and warrants exercisable for additional shares. The Fund has a beneficial ownership blocker that limits conversion of preferred stock to prevent ownership exceeding 9.99% of the common stock. The filing also details a letter agreement allowing the Fund to nominate up to two individuals to the Issuer's Board of Directors. The Reporting Persons acquired the securities for investment purposes and have no current plans to change control of the Issuer.